This is a working overview of Cyclic AMP, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
==== Training and qualification ==== In Europe, the training of physicians in Clinical/Medical Genetics is overseen by the Union Européenne des Médecins Spécialistes (UEMS). This organization aims to harmonize and raise the standards of medical specialist training across Europe. The UEMS has established European Training Requirements (ETR) for Medical Genetics to guide the education and training of medical geneticists. Individuals seeking acceptance into clinical genetics training programs must hold an MD, or in some countries, an MB ChB or MB BS degree. These qualifications ensure that trainees have the foundational medical knowledge required to specialize in Medical Genetics. The optimal training program involves a total of five years: one year of general medical training (the "common trunk", often covering fields such as general practice, pediatrics, obstetrics and gynecology, neurology, psychiatry, and internal medicine) followed by four years of specialized training in Medical Genetics. This specialized training should include at least two years of clinical patient care and at least six months in genetic laboratory diagnostics. Trainees' progress is evaluated through a structured program that begins with observation and progresses to independent practice under supervision, culminating in the ability to manage complex cases independently. Final certification involves a comprehensive assessment, which may include national examinations or the European Certificate in Medical Genetics and Genomics (ECMGG).
After the completion of the coupling reaction, a small percentage of the solid support-bound 5'-OH groups (0.1 to 1%) remains unreacted and needs to be permanently blocked from further chain elongation to prevent the formation of oligonucleotides with an internal base deletion commonly referred to as (n-1) shortmers. The unreacted 5'-hydroxy groups are, to a large extent, acetylated by the capping mixture. It has also been reported that phosphoramidites activated with 1H-tetrazole react, to a small extent, with the O6 position of guanosine. Upon oxidation with I2 /water, this side product, possibly via O6-N7 migration, undergoes depurination. The apurinic sites thus formed are readily cleaved in the course of the final deprotection of the oligonucleotide under the basic conditions (see below) to give two shorter oligonucleotides thus reducing the yield of the full-length product. The O6 modifications are rapidly removed by treatment with the capping reagent as long as the capping step is performed prior to oxidation with I2/water. The synthesis of oligonucleotide phosphorothioates (OPS, see below) does not involve the oxidation with I2/water, and, respectively, does not suffer from the side reaction described above. On the other hand, if the capping step is performed prior to sulfurization, the solid support may contain the residual acetic anhydride and N-methylimidazole left after the capping step.
== History == Fluvoxamine was developed by Kali-Duphar, part of Solvay Pharmaceuticals, Belgium, now Abbott Laboratories, and introduced as Floxyfral in Switzerland in 1983. It was approved by the U.S. Food and Drug Administration (FDA) in 1994, and introduced as Luvox in the US. In India, it is available, among several other brands, as Uvox by Abbott. It was one of the first SSRI antidepressants to be launched, and is prescribed in many countries to patients with major depression. It was the first SSRI, a non-TCA drug, approved by the U.S. FDA specifically for the treatment of OCD. At the end of 1995, more than ten million patients worldwide had been treated with fluvoxamine. Fluvoxamine was the first SSRI to be registered for the treatment of obsessive compulsive disorder in children by the FDA in 1997. In Japan, fluvoxamine was the first SSRI to be approved for the treatment of depression in 1999 and was later in 2005 the first drug to be approved for the treatment of social anxiety disorder. Fluvoxamine was the first SSRI approved for clinical use in the United Kingdom. Manufacturers include BayPharma, Synthon, and Teva, among others.
Sources: en.wikipedia.org
=== Enzymatic labeling === In enzymatic labeling, a DNA construct is first formed, using a gene and the DNA of a fluorescent protein. After transcription, a hybrid RNA + fluorescent is formed. The object of interest is attached to an enzyme that can recognize this hybrid DNA. Usually fluorescein is used as the fluorophore.
The substrates of this enzyme are D-glyceric acid, oxidised nicotinamide adenine dinucleotide (NAD+), and carbon dioxide. Its products are 2-hydroxy-3-oxosuccinic acid, reduced NADH, and a proton. The enzyme can use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-glycerate:NAD(P)+ oxidoreductase (carboxylating). This enzyme participates in glyoxylate and dicarboxylate metabolism.
=== Associated conditions === Joint hypermobility may be associated with other conditions. These include ADHD, autism, dyspraxia, fibromyalgia, hereditary connective tissue disorders, mitral valve prolapse, and anxiety disorders such as panic disorder. Joint hypermobility does not cause these other conditions. Most people with joint hypermobility do not have them. In people who do, the underlying cause can be a general syndrome that affects the whole body and brain (such as Autism or Fetal Alcohol Spectrum Disorders), or a genetic condition or disease that affects certain tissues (such as Ehlers-Danlos syndrome or lupus). Hypermobility may be a risk factor for temporomandibular joint dysfunction.
Sources: en.wikipedia.org
==== Quantum dot only solar cells ==== Aromatic self-assembled monolayers (SAMs) (such as 4-nitrobenzoic acid) can be used to improve the band alignment at electrodes for better efficiencies. This technique has provided a record power conversion efficiency (PCE) of 10.7%. The SAM is positioned between ZnO–PbS colloidal quantum dot (CQD) film junction to modify band alignment via the dipole moment of the constituent SAM molecule, and the band tuning may be modified via the density, dipole and the orientation of the SAM molecule.
A major function of FPR2 is to bind certain specialized pro-resolving mediators (SPMs)—including lipoxin (Lx)A4, AT-LxA4 (arachidonic acid metabolites), and resolvin D1 (RvD1), RvD2, and AT-RvD1 (derived from docosahexaenoic acid)—and to mediate their inflammation-resolving effects. In addition, FPR2 also responds to a wide range of peptides and proteins that may promote inflammation or regulate unrelated processes. The physiological role of FPR3 remains unclear.
== Relationship to other South Asians and West Asians == A 1985 study conducted by Roychoudhury AK and Nei M indicating the values of genetic distance showed that the Sinhalese, along with the four Indian subcontinent populations from Punjab, Gujarat, Andhra Pradesh, and Bangladesh, were closer to Afghans and Iranians than the neighboring East/Southeast Asian groups represented by the Bhutanese, Malays, Bataks in northern Sumatra, and the Chinese.
== History == Historically, the fish processing methods used for human consumption have been: fresh, canned, frozen, smoked or dehydrated - all of which would be used as a whole food rather than as an ingredient in other foods. Additionally, an industrial fish industry exists where whole fish and by products from fish processing have been cooked and dehydrated to form a product termed fish meal, which is used for animal feed, pet food and fish feed. With the evolution of refining and processing technology and expanded research on the nutrition of fish proteins and peptides, a new industry has developed for the specific purpose of producing a fish protein powder for human consumption with the intent of reaching new ingredient uses and markets. The FPP end product is now used in a variety of food ingredient applications including sports nutrition, food additives and supplements, all of which depend on the finished fish protein powder produced such that it is hygienically safe and also meets sensory requirements of taste, odor and function in prepared foods.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.